ResMed Inc. 10-Q Summary: Quarter Ended March 31, 1997
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1997, and the nine-month period ended on the same date. ResMed Inc. is a Delaware holding company for ResMed Holdings Ltd., an Australian entity that designs, manufactures, and markets devices for the evaluation and treatment of sleep disordered breathing, primarily obstructive sleep apnea. Principal manufacturing is located in Australia, with major distribution and sales sites in the United States, United Kingdom, and Europe.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 1997 | 9 Months Ended Mar 31, 1997 |
|---|---|---|
| Net Revenue | $12,468 | $35,196 |
| Gross Profit | $7,348 | $20,511 |
| Gross Margin | 59% | 58% |
| Operating Income | $2,219 | $5,644 |
| Net Income | $1,898 | $5,420 |
| Diluted EPS | $0.26 | $0.74 |
| Cash from Operations (9mo) | $6,681 | |
| Total Assets | $53,643 | |
| Working Capital | $33,513 | |
| Total Debt | $720 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 33% ($3.1M) for the quarter and 47% ($11.2M) for the nine months compared to the prior year periods. Growth was driven by increased unit sales of flow generators and accessories in North America and Europe.
- Margin Expansion: Gross margin improved to 59% for the quarter (from 49%) and 58% for the nine months (from 50%), attributed to higher sales of higher-margin products.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 40% for the quarter and 62% for the nine months. This was due to an increase in sales personnel (from 90 to 103), higher legal fees related to ongoing litigation, and expanded direct distribution in Europe. R&D expenses increased 66% for the quarter due to consultant usage and new product testing.
- Other Income: Other income declined 20% for the quarter primarily due to the cessation of Australian Federal Government export grants effective June 30, 1996. However, for the nine-month period, other income increased 29% due to $1.6M in foreign currency gains from option contracts.
Outlook, Risks, and Contingencies
- Liquidity: The company maintains strong liquidity with $27.3 million in cash and marketable securities as of March 31, 1997. Working capital increased to $33.7 million.
- Capital Expenditures: Capital spending for the nine months totaled $2.7 million, primarily for computer hardware/software, production tooling, and equipment.
- Legal Proceedings:
- Australia Patent Revocation: A final settlement of approximately $246,000 was reached regarding a revoked patent; this amount was already accrued.
- Respironics Litigation: Ongoing patent infringement suits in the U.S. and unfair trade practice claims in Australia (seeking ~$901,000). Management believes these will not have a material adverse effect but expects ongoing legal costs.
- Foreign Exchange Risk: The company is exposed to currency fluctuations affecting international sales and manufacturing costs, managed through foreign currency option contracts.
- Dividend: A dividend was declared in the form of preferred stock purchase rights (Rights Agreement dated April 23, 1997).
Investor Verification Checklist
- Verify the sustainability of the 59% gross margin given the significant increase in SG&A expenses (up 40% QoQ).
- Monitor the outcome of the Respironics litigation in the U.S. and Australia, specifically the potential for significant damages or injunctions.
- Assess the impact of the termination of Australian government export grants on future "Other Income" projections.
- Review the effectiveness of foreign currency hedging strategies given the company's exposure to the Australian Dollar, Pound Sterling, and Deutschmarks.
- Confirm the integration and financial contribution of the recent acquisitions (Priess and TQR Pty Limited silicone moulding operations).